TP53 and idiopathic pulmonary fibrosis: Based on this body of work, we strongly believe that a CSP7-based therapeutic that concurrently alters p53 expression in injured AECs and in fLfs will improve the outcomes of IPF or other ILDs in an effective and well-tolerated way.